A randomized phase II study of pemetrexed or RADOO1 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: Treatment rationale and protocol dynamics

Cesare Gridelli, Antonio Rossi, Floriana Morgillo, Maria Anna Bareschino, Paolo Maione, Massimo Di Maio, Fortunato Ciardiello

Research output: Contribution to journalArticlepeer-review

Abstract

In the current clinical trial summary, we present a randomized phase II trial of pemetrexed or RAD001 as second-line treatment of elderly patients with advanced non-small-cell lung cancer. The molecular and clinical rationale is reviewed. The primary endpoint is progression-free survival, and secondary endpoints include objective tumor response rates, disease control rates, safety, tolerability, and overall survival. Based on the statistical design, the investigators plan to enroll 92 elderly patients, 46 per arm.

Original languageEnglish
Pages (from-to)568-571
Number of pages4
JournalClinical Lung Cancer
Volume8
Issue number9
DOIs
Publication statusPublished - Nov 2007

Keywords

  • Chemotherapy
  • Everolimus
  • Mammalian target of rapamycin
  • Targeted therapy

ASJC Scopus subject areas

  • Cancer Research
  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'A randomized phase II study of pemetrexed or RADOO1 as second-line treatment of advanced non-small-cell lung cancer in elderly patients: Treatment rationale and protocol dynamics'. Together they form a unique fingerprint.

Cite this